EZR and osteosarcoma: The combined HR was 4.79 (95% CI: 1.50–15.30; Z = 2.64; P = 0.008), which demonstrated that ezrin immunoexpression was significantly associated with the poor OS of osteosarcoma patients (Figure 3).